Harrow
HROW37.4602.57% ( -0.990 )
Harrow (HROW)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the Unite...
- Open
- 39.162
- High
- 39.930
- Low
- 37.360
- Prev. Close
- 38.450
- Volume
- 516.68K
- Turnover
- 19.62M
- Avg Price
- 37.969
- Bid/Ask Ratio
- --
- Amplitude
- 6.68%
- 52wk High
- 54.850
- Volume Ratio
- 0.71
- Turnover Ratio
- 1.83%
Harrow Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$67.7580.86%
Forecast & RatingStrong buy
8analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · 18 hours ago
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
- PUBT · 18 hours ago
Harrow updates financial calendar with upcoming quarterly results release and investor call
- Global Report · 2 days ago, 04:13 AM
The Age of Compliance and Desperation: Inside the Mid-Cap Crucible
- Global Report · Jul 24 at 04:13 AM
Niche Players Accelerate 2026 Capital Deployment: Equinox Revenue Doubles as iPower Pivots to AI
- Global Report · Jul 22 at 04:18 AM
From Nuclear Tech to AI Liquid Cooling: Unpacking Micro-Cap Overhauls
- Simplywall · Jul 20 at 08:08 PM
Can New Retina Data Deepen Harrow’s (HROW) Moat In Ophthalmology Or Just Refine Its Story?
